Analysis of Clinical Applications of Three Classes of CDK4/6 Inhibitors for Breast Cancer
Breast cancer has become the most common malignant tumor among women worldwide, and continuous innovation in treatment methods has greatly improved patients' overall survival and prognosis. Approximately 70% of breast cancer patients are hormone receptor-positive and human epidermal growth factor receptor 2-negative.
CDK4/6 inhibitors are core targeted therapies for HR-positive, HER2-negative advanced breast cancer. By selectively inhibiting cyclin-dependent kinases 4 and 6, they block the tumor cell proliferation cycle, significantly prolonging progression-free survival and overall survival.
Dengyue Pharmaceutical will summarize three CDK4/6 inhibitors for treating breast cancer patients to help clinicians and industry readers quickly grasp their target profile and indications. Currently, palbociclib, dalciribine is available in China, and leroximately leroximate tablets are all mainstream clinical choices, each with its own characteristics in terms of indications, safety, and applicable populations.
Common Mechanism of Action of the Three Drugs
CDK4/6 binds to cyclin D, phosphorylating retinoblastoma protein and releasing the E2F transcription factor, which drives cell proliferation. This pathway is abnormally activated in HR+ breast cancer. All three drugs selectively inhibit CDK4/6, restoring Rb function and arresting the tumor cell cycle. All three drugs require combination therapy with aromatase inhibitors or endocrine therapy such as fulvestrant to overcome endocrine resistance.
Palbociclib:
The world's first marketed CDK4/6 inhibitor, a classic benchmark drug.
Indications: HR-positive, HER2-negative locally advanced or metastatic breast cancer.
Can be used in combination with aromatase inhibitors or fulvestrant.
Dalcilibalyxate:
A Chinese-developed CDK4/6 inhibitor, based on data from the Chinese population.
Indications: HR-positive, HER2-negative recurrent or metastatic breast cancer.
In combination with fulvestrant for patients whose condition has progressed on prior endocrine therapy.
Lerociclib Hydrochloride Tablets:
A new generation of highly selective CDK4/6 inhibitors with stronger target selectivity.
Indications: HR-positive, HER2-negative locally advanced or metastatic breast cancer.
Can be used in combination with endocrine therapy for first-line and later-line treatment.
Safety and Adverse Reactions Highlights
Common Adverse Reactions: Neutropenia is the most common adverse reaction for all three drugs, mostly grade I-II, which can be resolved by dose adjustment and short-term drug discontinuation. Febrile neutropenia has a low incidence.
Differences and Characteristics:
● Palbociclib: May cause abnormal liver function, fatigue, and gastrointestinal reactions; liver function monitoring is required.
● Dalcilib: Sufficient data in the Chinese population; mature experience in managing myelosuppression.
● Leroxib: High selectivity, minimal interference with targets such as CDK9, better overall tolerability, and relatively lower incidence of diarrhea and fatigue.
Comparison of Clinical Applications of the Three Drugs
Efficacy Consistency: PFS was significantly prolonged for all three drugs.
Cross-Trial Comparison: Palbociclib ≈ 24-27 months, Dalcilib 30.6 months, Leroxib HR 0.45 (advantage). OS data maturity differs, but all show a trend towards benefit. Data on Dalcilib is most abundant in the Chinese population, while Leroxib shows a significant advantage in patients with refractory populations.
Safety Differences: Palbociclib primarily causes neutropenia but it is manageable; Darcitabine has low non-hematologic toxicity and is safer on the liver; Leroxibine has the best overall toxicity profile and the best adherence.
Suitable Populations:
● Premenopausal/Perimenopause: Darcitabine and Leroxibine have broader indication coverage.
● Primary endocrine resistance/visceral crisis: Leroxibine or Darcitabine are preferred.
● Elderly/Comorbid patients: Leroxibine has a significant tolerability advantage.
● Economic/Medical Insurance Factors: All three drugs are included in relevant catalogs or dual-channel management, depending on the region.
No head-to-head trials have been conducted; selection is based on the patient's bone marrow reserve, gastrointestinal function, liver and kidney function, previous treatment, adherence, and physician experience.
The availability of original drugs in China provides patients with more accessible and cost-effective options, supporting precision medicine. This constitutes a matrix of highly effective, safe, and accessible CDK4/6 inhibitor treatments for HR-positive advanced breast cancer. Clinical selection should be individualized, taking into account factors such as the number of lines of treatment, comorbidities, medication adherence, and drug accessibility, to significantly improve patients' quality of life while prolonging survival. Future adjuvant therapies and new strategies combining adjuvant therapies with ADCs/immunotherapy will further expand the beneficiary population.
Dengyue Pharmaceutical reminds you that clinical decisions should be based on the latest guidelines, patient wishes, and multidisciplinary discussions, with regular follow-up assessments of efficacy and safety. For specific prescriptions, please consult a specialist.